An international multidisciplinary consensus statement on MAFLD and the risk of CVD

Xiao Dong Zhou; Giovanni Targher; Christopher D. Byrne; Virend Somers; Seung Up Kim; C. Anwar A. Chahal; Vincent Wai Sun Wong; Jingjing Cai; Michael D. Shapiro; Mohammed Eslam; Philippe Gabriel Steg; Ki Chul Sung; Anoop Misra; Jian Jun Li; Carlos Brotons; Yuli Huang; George V. Papatheodoridis; Aijun Sun; Yusuf Yilmaz; Wah Kheong Chan; Hui Huang; Nahum Méndez-Sánchez; Saleh A. Alqahtani; Helena Cortez-Pinto; Gregory Y.H. Lip; Robert J. de Knegt; Ponsiano Ocama; Manuel Romero-Gomez; Marat Fudim; Giada Sebastiani; Jang Won Son; John D. Ryan; Ignatios Ikonomidis; Sombat Treeprasertsuk; Daniele Pastori; Monica Lupsor-Platon; Herbert Tilg; Hasmik Ghazinyan; Jerome Boursier; Masahide Hamaguchi; Mindie H. Nguyen; Jian Gao Fan; George Boon Bee Goh; Mamun Al Mahtab; Saeed Hamid; Nilanka Perera; Jacob George; Ming Hua Zheng

doi:10.1007/s12072-023-10543-8

An international multidisciplinary consensus statement on MAFLD and the risk of CVD

Xiao Dong Zhou, Giovanni Targher, Christopher D. Byrne, Virend Somers, Seung Up Kim, C. Anwar A. Chahal, Vincent Wai Sun Wong, Jingjing Cai, Michael D. Shapiro, Mohammed Eslam, Philippe Gabriel Steg, Ki Chul Sung, Anoop Misra, Jian Jun Li, Carlos Brotons, Yuli Huang, George V. Papatheodoridis, Aijun Sun, Yusuf Yilmaz, Wah Kheong ChanHui Huang, Nahum Méndez-Sánchez, Saleh A. Alqahtani, Helena Cortez-Pinto, Gregory Y.H. Lip, Robert J. de Knegt, Ponsiano Ocama, Manuel Romero-Gomez, Marat Fudim, Giada Sebastiani, Jang Won Son, John D. Ryan, Ignatios Ikonomidis, Sombat Treeprasertsuk, Daniele Pastori, Monica Lupsor-Platon, Herbert Tilg, Hasmik Ghazinyan, Jerome Boursier, Masahide Hamaguchi, Mindie H. Nguyen, Jian Gao Fan, George Boon Bee Goh, Mamun Al Mahtab, Saeed Hamid, Nilanka Perera, Jacob George, Ming Hua Zheng

Department of Medicine, Medical College, Pakistan

Research output: Contribution to journal › Article › peer-review

82 Citations (Scopus)

Abstract

Background: Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of ~ 25–30% and is also associated with cardiovascular disease (CVD). Since systemic metabolic dysfunction underlies its pathogenesis, the term metabolic (dysfunction)-associated fatty liver disease (MAFLD) has been proposed for this condition. MAFLD is closely intertwined with obesity, type 2 diabetes mellitus and atherogenic dyslipidemia, which are established cardiovascular risk factors. Unlike CVD, which has received attention in the literature on fatty liver disease, the CVD risk associated with MAFLD is often underestimated, especially among Cardiologists. Methods and results: A multidisciplinary panel of fifty-two international experts comprising Hepatologists, Endocrinologists, Diabetologists, Cardiologists and Family Physicians from six continents (Asia, Europe, North America, South America, Africa and Oceania) participated in a formal Delphi survey and developed consensus statements on the association between MAFLD and the risk of CVD. Statements were developed on different aspects of CVD risk, ranging from epidemiology to mechanisms, screening, and management. Conculsions: The expert panel identified important clinical associations between MAFLD and the risk of CVD that could serve to increase awareness of the adverse metabolic and cardiovascular outcomes of MAFLD. Finally, the expert panel also suggests potential areas for future research.

Original language	English
Pages (from-to)	773-791
Number of pages	19
Journal	Hepatology International
Volume	17
Issue number	4
DOIs	https://doi.org/10.1007/s12072-023-10543-8
Publication status	Published - Aug 2023

Keywords

Cardiovascular disease
Consensus
Delphi survey
MAFLD
Metabolic (dysfunction)-associated fatty liver disease
Non-alcoholic fatty liver disease

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12072-023-10543-8

Cite this

Zhou, X. D., Targher, G., Byrne, C. D., Somers, V., Kim, S. U., Chahal, C. A. A., Wong, V. W. S., Cai, J., Shapiro, M. D., Eslam, M., Steg, P. G., Sung, K. C., Misra, A., Li, J. J., Brotons, C., Huang, Y., Papatheodoridis, G. V., Sun, A., Yilmaz, Y., ... Zheng, M. H. (2023). An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatology International, 17(4), 773-791. https://doi.org/10.1007/s12072-023-10543-8

@article{cbbc8921e50a4891b9ccda9dc37f2023,

title = "An international multidisciplinary consensus statement on MAFLD and the risk of CVD",

abstract = "Background: Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of ~ 25–30% and is also associated with cardiovascular disease (CVD). Since systemic metabolic dysfunction underlies its pathogenesis, the term metabolic (dysfunction)-associated fatty liver disease (MAFLD) has been proposed for this condition. MAFLD is closely intertwined with obesity, type 2 diabetes mellitus and atherogenic dyslipidemia, which are established cardiovascular risk factors. Unlike CVD, which has received attention in the literature on fatty liver disease, the CVD risk associated with MAFLD is often underestimated, especially among Cardiologists. Methods and results: A multidisciplinary panel of fifty-two international experts comprising Hepatologists, Endocrinologists, Diabetologists, Cardiologists and Family Physicians from six continents (Asia, Europe, North America, South America, Africa and Oceania) participated in a formal Delphi survey and developed consensus statements on the association between MAFLD and the risk of CVD. Statements were developed on different aspects of CVD risk, ranging from epidemiology to mechanisms, screening, and management. Conculsions: The expert panel identified important clinical associations between MAFLD and the risk of CVD that could serve to increase awareness of the adverse metabolic and cardiovascular outcomes of MAFLD. Finally, the expert panel also suggests potential areas for future research.",

keywords = "Cardiovascular disease, Consensus, Delphi survey, MAFLD, Metabolic (dysfunction)-associated fatty liver disease, Non-alcoholic fatty liver disease",

author = "Zhou, {Xiao Dong} and Giovanni Targher and Byrne, {Christopher D.} and Virend Somers and Kim, {Seung Up} and Chahal, {C. Anwar A.} and Wong, {Vincent Wai Sun} and Jingjing Cai and Shapiro, {Michael D.} and Mohammed Eslam and Steg, {Philippe Gabriel} and Sung, {Ki Chul} and Anoop Misra and Li, {Jian Jun} and Carlos Brotons and Yuli Huang and Papatheodoridis, {George V.} and Aijun Sun and Yusuf Yilmaz and Chan, {Wah Kheong} and Hui Huang and Nahum M{\'e}ndez-S{\'a}nchez and Alqahtani, {Saleh A.} and Helena Cortez-Pinto and Lip, {Gregory Y.H.} and {de Knegt}, {Robert J.} and Ponsiano Ocama and Manuel Romero-Gomez and Marat Fudim and Giada Sebastiani and Son, {Jang Won} and Ryan, {John D.} and Ignatios Ikonomidis and Sombat Treeprasertsuk and Daniele Pastori and Monica Lupsor-Platon and Herbert Tilg and Hasmik Ghazinyan and Jerome Boursier and Masahide Hamaguchi and Nguyen, {Mindie H.} and Fan, {Jian Gao} and Goh, {George Boon Bee} and {Al Mahtab}, Mamun and Saeed Hamid and Nilanka Perera and Jacob George and Zheng, {Ming Hua}",

note = "Publisher Copyright: {\textcopyright} 2023, Asian Pacific Association for the Study of the Liver.",

year = "2023",

month = aug,

doi = "10.1007/s12072-023-10543-8",

language = "English",

volume = "17",

pages = "773--791",

journal = "Hepatology International",

issn = "1936-0533",

publisher = "Springer New York",

number = "4",

}

Zhou, XD, Targher, G, Byrne, CD, Somers, V, Kim, SU, Chahal, CAA, Wong, VWS, Cai, J, Shapiro, MD, Eslam, M, Steg, PG, Sung, KC, Misra, A, Li, JJ, Brotons, C, Huang, Y, Papatheodoridis, GV, Sun, A, Yilmaz, Y, Chan, WK, Huang, H, Méndez-Sánchez, N, Alqahtani, SA, Cortez-Pinto, H, Lip, GYH, de Knegt, RJ, Ocama, P, Romero-Gomez, M, Fudim, M, Sebastiani, G, Son, JW, Ryan, JD, Ikonomidis, I, Treeprasertsuk, S, Pastori, D, Lupsor-Platon, M, Tilg, H, Ghazinyan, H, Boursier, J, Hamaguchi, M, Nguyen, MH, Fan, JG, Goh, GBB, Al Mahtab, M, Hamid, S, Perera, N, George, J & Zheng, MH 2023, 'An international multidisciplinary consensus statement on MAFLD and the risk of CVD', Hepatology International, vol. 17, no. 4, pp. 773-791. https://doi.org/10.1007/s12072-023-10543-8

TY - JOUR

T1 - An international multidisciplinary consensus statement on MAFLD and the risk of CVD

AU - Zhou, Xiao Dong

AU - Targher, Giovanni

AU - Byrne, Christopher D.

AU - Somers, Virend

AU - Kim, Seung Up

AU - Chahal, C. Anwar A.

AU - Wong, Vincent Wai Sun

AU - Cai, Jingjing

AU - Shapiro, Michael D.

AU - Eslam, Mohammed

AU - Steg, Philippe Gabriel

AU - Sung, Ki Chul

AU - Misra, Anoop

AU - Li, Jian Jun

AU - Brotons, Carlos

AU - Huang, Yuli

AU - Papatheodoridis, George V.

AU - Sun, Aijun

AU - Yilmaz, Yusuf

AU - Chan, Wah Kheong

AU - Huang, Hui

AU - Méndez-Sánchez, Nahum

AU - Alqahtani, Saleh A.

AU - Cortez-Pinto, Helena

AU - Lip, Gregory Y.H.

AU - de Knegt, Robert J.

AU - Ocama, Ponsiano

AU - Romero-Gomez, Manuel

AU - Fudim, Marat

AU - Sebastiani, Giada

AU - Son, Jang Won

AU - Ryan, John D.

AU - Ikonomidis, Ignatios

AU - Treeprasertsuk, Sombat

AU - Pastori, Daniele

AU - Lupsor-Platon, Monica

AU - Tilg, Herbert

AU - Ghazinyan, Hasmik

AU - Boursier, Jerome

AU - Hamaguchi, Masahide

AU - Nguyen, Mindie H.

AU - Fan, Jian Gao

AU - Goh, George Boon Bee

AU - Al Mahtab, Mamun

AU - Hamid, Saeed

AU - Perera, Nilanka

AU - George, Jacob

AU - Zheng, Ming Hua

PY - 2023/8

Y1 - 2023/8

N2 - Background: Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of ~ 25–30% and is also associated with cardiovascular disease (CVD). Since systemic metabolic dysfunction underlies its pathogenesis, the term metabolic (dysfunction)-associated fatty liver disease (MAFLD) has been proposed for this condition. MAFLD is closely intertwined with obesity, type 2 diabetes mellitus and atherogenic dyslipidemia, which are established cardiovascular risk factors. Unlike CVD, which has received attention in the literature on fatty liver disease, the CVD risk associated with MAFLD is often underestimated, especially among Cardiologists. Methods and results: A multidisciplinary panel of fifty-two international experts comprising Hepatologists, Endocrinologists, Diabetologists, Cardiologists and Family Physicians from six continents (Asia, Europe, North America, South America, Africa and Oceania) participated in a formal Delphi survey and developed consensus statements on the association between MAFLD and the risk of CVD. Statements were developed on different aspects of CVD risk, ranging from epidemiology to mechanisms, screening, and management. Conculsions: The expert panel identified important clinical associations between MAFLD and the risk of CVD that could serve to increase awareness of the adverse metabolic and cardiovascular outcomes of MAFLD. Finally, the expert panel also suggests potential areas for future research.

AB - Background: Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of ~ 25–30% and is also associated with cardiovascular disease (CVD). Since systemic metabolic dysfunction underlies its pathogenesis, the term metabolic (dysfunction)-associated fatty liver disease (MAFLD) has been proposed for this condition. MAFLD is closely intertwined with obesity, type 2 diabetes mellitus and atherogenic dyslipidemia, which are established cardiovascular risk factors. Unlike CVD, which has received attention in the literature on fatty liver disease, the CVD risk associated with MAFLD is often underestimated, especially among Cardiologists. Methods and results: A multidisciplinary panel of fifty-two international experts comprising Hepatologists, Endocrinologists, Diabetologists, Cardiologists and Family Physicians from six continents (Asia, Europe, North America, South America, Africa and Oceania) participated in a formal Delphi survey and developed consensus statements on the association between MAFLD and the risk of CVD. Statements were developed on different aspects of CVD risk, ranging from epidemiology to mechanisms, screening, and management. Conculsions: The expert panel identified important clinical associations between MAFLD and the risk of CVD that could serve to increase awareness of the adverse metabolic and cardiovascular outcomes of MAFLD. Finally, the expert panel also suggests potential areas for future research.

KW - Cardiovascular disease

KW - Consensus

KW - Delphi survey

KW - MAFLD

KW - Metabolic (dysfunction)-associated fatty liver disease

KW - Non-alcoholic fatty liver disease

UR - http://www.scopus.com/inward/record.url?scp=85159655410&partnerID=8YFLogxK

U2 - 10.1007/s12072-023-10543-8

DO - 10.1007/s12072-023-10543-8

M3 - Article

C2 - 37204656

AN - SCOPUS:85159655410

SN - 1936-0533

VL - 17

SP - 773

EP - 791

JO - Hepatology International

JF - Hepatology International

IS - 4

ER -

An international multidisciplinary consensus statement on MAFLD and the risk of CVD

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this